Monday, June 30, 2008 at 7:21 PM Posted by Ananth Krishna
Labels: Order Book and Deal 0 comments
at 7:19 PM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 7:17 PM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 7:17 PM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 7:16 PM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 7:15 PM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 7:14 PM Posted by Ananth Krishna
Labels: Market Commentary 0 comments
at 7:14 PM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 7:13 PM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 7:12 PM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 10:01 AM Posted by Ananth Krishna
Labels: Investor's Guide 0 comments
at 9:57 AM Posted by Ananth Krishna
Labels: U.S. Market 0 comments
at 8:48 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 8:47 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 8:46 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 8:45 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 8:44 AM Posted by Ananth Krishna
Labels: Market Commentary 0 comments
at 8:42 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 8:41 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 8:38 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 8:37 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 8:34 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
Friday, June 27, 2008 at 8:42 PM Posted by Ananth Krishna
Labels: U.S. Market 0 comments
at 7:38 PM Posted by Ananth Krishna
Labels: U.S. Market 0 comments
at 5:28 AM Posted by Ananth Krishna
Labels: Crude Oil and Gold 0 comments
at 5:06 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 5:04 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 4:07 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 4:05 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 4:05 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 4:04 AM Posted by Ananth Krishna
Labels: Order Book and Deal 0 comments
at 4:03 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 4:02 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 4:01 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 3:59 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
Thursday, June 26, 2008 at 7:53 PM Posted by Ananth Krishna
Labels: U.S. Market 0 comments
at 8:17 AM Posted by Ananth Krishna
Labels: U.S. Market 0 comments
at 8:13 AM Posted by Ananth Krishna
Labels: U.S. Market 0 comments
at 8:13 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 8:11 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 6:40 AM Posted by Ananth Krishna
Labels: Order Book and Deal 0 comments
at 6:39 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 6:38 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 6:37 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 6:36 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 6:35 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 6:35 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 6:34 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 6:33 AM Posted by Ananth Krishna
Labels: IPO 0 comments
at 6:32 AM Posted by Ananth Krishna
Labels: Dividend 0 comments
at 6:17 AM Posted by Ananth Krishna
Labels: Crude Oil and Gold 0 comments
at 6:16 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 6:15 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 6:12 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
at 5:58 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
Wednesday, June 25, 2008 at 8:23 AM Posted by Ananth Krishna
Labels: Indian Market 0 comments
at 8:15 AM Posted by Ananth Krishna
Labels: Order Book and Deal 0 comments
at 8:10 AM Posted by Ananth Krishna
Key Highlights:
GMR, a global infrastructure company with business presence in energy, airports, highways and urban infrastructure, today announced the signing of definitive documentation for the acquisition of 50% stake in InterGen N. V., a leading global power generation company. InterGen N V has power plants located across the UK, the Netherlands, Mexico, Australia and the Philippines, with total net capacity (net of auxiliary) of 12,756 MW (8,086 MW of operational capacity and 4,680 MW of asset under development). The transaction is subject to regulatory approvals in each country where InterGen has operations and is expected to close in the third quarter of 2008.
This transaction, valued at $1.1 billion, is the largest ever acquisition of an energy utility company by an Indian company. GMR Infrastructure (Malta) Ltd signed the share purchase agreement with AIG Highstar to acquire 50% equity stake in InterGen N. V. GMR expects to close the transaction in CY 2008. N M Rothschild & Sons worked as the sole exclusive financial advisor whereas White & Case LLP worked as Legal advisor to the GMR Group on this transaction.
Speaking on the occasion, Mr G M Rao, Group Chairman, GMR Group said: "The acquisition of a 50% equity stake in InterGen N V is an integral part of our global strategy to be the world's leading energy and infrastructure company. This acquisition will provide us a platform to expand in InterGen's existing geographies and new geographies of strategic importance to both GMR and Teachers'. Such growth will be supported by the strong management, high quality assets and a partner like Teachers', which is also a leading global infrastructure investor."
Explaining the alignment of interests, Mr Rao said: "Our core experience in the 'energy business life cycle', covers identifying opportunities, developing assets in greenfield areas, strong project management skills, financial structuring and efficient operations. We found the same expertise in InterGen, which encouraged us to go ahead with the acquisition and synergise our growth. InterGen has consistently achieved economic returns in developed markets, comparable to those in emerging markets."
Christopher Lee, Founding partner of AIG Highstar said "We have greatly enjoyed working with InterGen management and our partners at Teachers' during the period of our ownership interest in this business. We are confident that GMR will be a great new partner for InterGen as it continues to the next level of well deserved success".
Neil Smith, CEO of InterGen NV added "We are very pleased that GMR, with its significant power and infrastructure development experience, has made this strategic investment in InterGen. This is a positive step in strengthening our position as a leading owner, operator and developer of global power projects".
Labels: Acquisition 0 comments
at 8:08 AM Posted by Ananth Krishna
Labels: Bonus 0 comments
at 8:07 AM Posted by Ananth Krishna
Ranbaxy Laboratories Ltd (RLL), on June 25, 2008 announced that the Company has received tentative approval from the U.S. Food and Drug Administration to manufacture and market Valganciclovir Hydrochloride Tablets, 450 mg. Total annual market sales for Valganciclovir HCl Tablets were $239 million (IMS – MAT: March 2008).
Ranbaxy believes that it has First-to-File status on Valganciclovir tablets, thereby providing a potential of 180-days of marketing exclusivity, offering a significant opportunity in the future.
Valganciclovir HCl Tablets are indicated for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). Valganciclovir HCl is also indicated for the prevention of cytomegalovirus (CMV) disease in kidney, heart and kidney-pancreas transplant patients at high risk (Donor CMV seropositive/Recipient CMV seronegative [(D+/R-)]).
"Ranbaxy is pleased to receive this tentative approval for Valganciclovir Hydrochloride Tablets, a medicine that has established its clinical value and utility over time. It will be launched by Ranbaxy upon receiving final approval and resolution of litigation currently pending in Federal District Court, as an affordably priced alternative to the branded product, Valcyte. This product formulation will further expand our portfolio of affordable generic alternatives and will be available to all classes of trade,†said Bill Winter, Vice President of Trade Sales for RPI, USA. “This represents another potentially strong market entry for Ranbaxy medicines from among our pipeline of patent challenges, and offers us a significant future opportunity,†Winter added.
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, USA, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.
Labels: Indian Market 0 comments
at 8:05 AM Posted by Ananth Krishna
Labels: Acquisition 0 comments
at 8:01 AM Posted by Ananth Krishna
Labels: Order Book and Deal 0 comments
at 7:49 AM Posted by Ananth Krishna
Labels: Result corner 0 comments
Powered byIP2Location.com
Minyx v2.0 template es un theme creado por Spiga.